EUVIMEDEUVIMED entdecken
Crossref

The treatment of deep venous thrombosis with the use of an oral thrombin inhibitor

E. Yu. Soldatsky, I. S. Lebedev, I. A. Zolotukhin

Flebologiia · 2015

DOI: 10.17116/flebo20159126-29 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Flebologiia, 2015. Verfasst von E. Yu. Soldatsky und 2 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

the tolerance to dabigatran etexilate and the patients’ compliance with the prescribed treatment were estimated.

Results

None of the patient exhibited the signs of recurrent venous thromboembolism (95% confidence interval 0—14.6%). Hemorrhagic episodes during the 3 month observation period were recorded in 4 (12.5%) patients (95% confidence interval 4—30%). The cases of severe hemorrhage were totally absent. Only one (3%) patient developed an adverse reaction (tachycardia). Compliance with the prescribed therapy was estimated at 94%.

Conclusion

The application of dabigatran etexilate in the routine clinical practice has excellent prospects due to its high effectiveness and safety for the patients presenting with deep venous thrombosis.

Zitieren

APA

Soldatsky, E. Y., Lebedev, I. S., & Zolotukhin, I. A. (2015). The treatment of deep venous thrombosis with the use of an oral thrombin inhibitor. Flebologiia. https://doi.org/10.17116/flebo20159126-29

Vancouver

Soldatsky EY, Lebedev IS, Zolotukhin IA. The treatment of deep venous thrombosis with the use of an oral thrombin inhibitor. Flebologiia. 2015. doi:10.17116/flebo20159126-29

BibTeX
@article{Soldatsky2015,
  author = {Soldatsky, E. Yu. and Lebedev, I. S. and Zolotukhin, I. A.},
  title = {The treatment of deep venous thrombosis with the use of an oral thrombin inhibitor},
  journal = {Flebologiia},
  year = {2015},
  doi = {10.17116/flebo20159126-29}
}
Kostenlos starten →